Antimicrobiano prometedor también ataca virus y estimula al sistema inmune

Un prometedor agente antimicrobiano con actividad reconocida en la eliminación de bacterias ha demostrado también su utilidad en la defensa contra virus y en la estimulación del sistema inmune innato según reportan investigadores del National Jewish Health. En el trabajo publicado el 4 de junio en la Journal of Investigative Dermatology, Michael Howell, PhD, profesor asistente de Pediatría y sus colegas demostraron que el compuesto sintético CSA-13 podía matar los virus vaccinia en cultivos celulares y en ratones. Adicionalmente mostraron que el CSA-13 estimula a las células a producir sus propias proteínas antimicrobianas.
“Este antimicrobiano está demostrando una amplia efectividad”, dijo el Dr. Howell. “Aunque nuestros experimentos estaban diseñados para probar su habilidad para atacar los virus vaccinia, su habilidad para estimular el sistema inmune resultó una observación sorprendente”
http://www.eurekalert.org/pub_releases/2009-06/njma-paa060309.php

“This compound is demonstrating broad effectiveness,” said Dr. Howell. “While our experiments were designed to test its ability to attack the vaccinia virus, its immune-stimulating ability was a surprising observation.”
CSA-13 is one of a class of compounds known as ceragenins, which were developed by Brigham Young University Professor Paul Savage to mimic antimicrobial proteins that occur naturally in the body. The ceragenins are smaller than antimicrobial proteins, and are not as vulnerable to degradation in the body. They have previously been shown to be effective against a variety of bacterial species.
Dr. Howell and his colleagues wanted to learn if CSA-13 could fight vaccinia virus infections. Vaccinia virus is closely related to the organism that causes smallpox and is used in smallpox vaccines. However, millions of people in the United States who have had eczema are susceptible to a serious and potentially fatal complication of the vaccination, known as eczema vaccinatum, which occurs when the vaccinia virus infects the skin. Dr. Howell is part of a team, led by Professor of Allergy and Clinical Immunology Donald Leung, MD, PhD, that is seeking protection against this complication so that eczema patients could receive the vaccination in case of a bioterrorist attack with smallpox.
CSA-13 demonstrated effectiveness against vaccinia in three different tests. When CSA-13 and vaccinia virus were directly incubated together, the CSA-13 killed more than 96% of the virus at a 25 micromolar concentration. When CSA-13 was added to cells infected with vaccinia, it both reduced vaccinia virus gene expression and allowed more of the infected cells to survive. Finally, the researchers infected immune-compromised mice with vaccinia virus, then applied CSA-13 onto their skin. The CSA-13 reduced the number of skin lesions caused by vaccinia virus.
“These experiments definitively showed for the first time CSA-13 can effectively fight vaccinia virus infections,” said senior author Dr. Leung.
Within their experiments, the researchers found that, in addition to directly killing the virus, CSA-13 also stimulated cells to produce their own antimicrobial proteins, LL-37 and HBD-3. Dr. Howell and colleagues have previously shown that these antimicrobial proteins also exhibit antiviral activity against vaccinia virus.
“We knew from our plaque assays, that CSA-13 was directly killing the virus,” said Dr. Howell. “But these experiments show that it also stimulates cells to produce their own antimicrobial proteins, which contribute to its disease-fighting capabilities. Our next step is to learn how CSA-13 stimulates cells’ own innate immune defenses.”